HC Wainwright set a $12.00 price target on Eyenovia (NASDAQ:EYEN) in a research note issued to investors on Tuesday morning. The firm currently has a buy rating on the stock.
EYEN has been the subject of several other research reports. Zacks Investment Research upgraded shares of Eyenovia from a hold rating to a buy rating and set a $6.25 target price for the company in a research report on Friday, August 17th. ValuEngine upgraded shares of Eyenovia from a hold rating to a buy rating in a research report on Thursday, November 1st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $17.63.
Shares of Eyenovia stock opened at $4.00 on Tuesday. The firm has a market cap of $40.56 million and a price-to-earnings ratio of -1.83. Eyenovia has a 52 week low of $2.60 and a 52 week high of $10.74.
Eyenovia (NASDAQ:EYEN) last issued its earnings results on Tuesday, November 13th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). On average, equities research analysts forecast that Eyenovia will post -1.65 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Uniplan Investment Counsel Inc. increased its position in shares of Eyenovia by 11.8% in the 3rd quarter. Uniplan Investment Counsel Inc. now owns 385,624 shares of the company’s stock valued at $1,550,000 after buying an additional 40,624 shares in the last quarter. Fairpointe Capital LLC increased its position in shares of Eyenovia by 140.7% in the 3rd quarter. Fairpointe Capital LLC now owns 119,526 shares of the company’s stock valued at $480,000 after buying an additional 69,877 shares in the last quarter. Finally, Vanguard Group Inc. bought a new stake in shares of Eyenovia in the 3rd quarter valued at $157,000. Institutional investors and hedge funds own 12.28% of the company’s stock.
Eyenovia Company Profile
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Featured Article: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.